financetom
Business
financetom
/
Business
/
Dream Residential REIT To Be Acquired By Morgan Properties For Near US$354 Million
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Dream Residential REIT To Be Acquired By Morgan Properties For Near US$354 Million
Aug 21, 2025 5:36 AM

08:02 AM EDT, 08/21/2025 (MT Newswires) -- DREAM RESIDENTIAL REAL ESTATE INVESTMENT TRUST (DRR-U.TO, DRR-UN.TO) announced Thursday that its board of trustees has completed its strategic review process and has entered into an arrangement agreement that will see Morgan Properties acquire the REIT in an all-cash transaction valued at approximately US$354 million.

Under the terms of the arrangement agreement, Dream Residential REIT unitholders and DRR Holdings LLC Class B unitholders will each receive cash consideration of US$10.80 per unit of the REIT and per Class B unit of DRR Holdings LLC. A statement noted the transaction price represents a premium of 60% to the closing Trust Unit price on the TSX as of February 19, 2025, the last trading day prior to the announcement of the Strategic Review. Furthermore, it noted, the transaction price represents an 18% premium to the closing Trust Unit price on the TSX as of August 20, 2025, the last trading day prior to the announcement of the transaction.

"Following a comprehensive review, the Board has determined that the Transaction is in the best interest of the REIT," said Vicky Schiff, Chair of Dream Residential REIT's board of trustees.

The board is unanimously recommending that Unitholders vote in favour of the transaction.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Johnson & Johnson to invest $2 billion to boost US manufacturing as drug tariffs loom
Johnson & Johnson to invest $2 billion to boost US manufacturing as drug tariffs loom
Aug 21, 2025
(Reuters) -Johnson & Johnson ( JNJ ) committed to invest $2 billion in North Carolina on Thursday to expand the drugmaker's U.S. manufacturing presence as potential drug import duties from President Donald Trump's administration loom. J&J said it plans to build a new facility at Tokyo-based Fujifilm Diosynth's manufacturing site in Holly Springs, North Carolina, over the next 10 years....
Yatsen Reports Q2 Adjusted Earnings, Higher Revenue; Q3 Sales Outlook Set
Yatsen Reports Q2 Adjusted Earnings, Higher Revenue; Q3 Sales Outlook Set
Aug 21, 2025
05:25 AM EDT, 08/21/2025 (MT Newswires) -- Yatsen Holding ( YSG ) reported Q2 non-GAAP earnings Thursday of 0.13 Chinese renminbi ($0.02) per diluted American depositary share, swinging from a loss of 0.67 renminbi a year earlier. Analyst estimates were not readily available for comparison. Net revenue for the quarter ended June 30 was 1.09 billion renminbi, compared with 794.5...
Chinese cosmetics firm Yatsen Q2 revenue rises
Chinese cosmetics firm Yatsen Q2 revenue rises
Aug 21, 2025
Overview * Yatsen Q2 2025 rev rises 36.8% yr/yr to RMB1.09 bln * Net loss narrows 77.2% to RMB19.5 mln, non-GAAP net income positive * Gross margin improves to 78.3%, driven by higher-margin product sales Outlook * Yatsen expects Q3 2025 net revenues between RMB778.6 mln and RMB880.1 mln * Company forecasts Q3 2025 revenue growth of 15% to 30%...
Alvotech Says European Commission Approved Mynzepli to Treat Retinal Diseases
Alvotech Says European Commission Approved Mynzepli to Treat Retinal Diseases
Aug 21, 2025
05:29 AM EDT, 08/21/2025 (MT Newswires) -- Alvotech ( ALVO ) and UK-based Advanz Pharma said Thursday that their Mynzepli fusion protein was approved by the European Commission to treat retinal diseases, including neovascular age-related macular degeneration. The companies said the approval was based on non-clinical and clinical similarity data, which included a confirmatory efficacy study comparing Mynzepli with Bayer's...
Copyright 2023-2025 - www.financetom.com All Rights Reserved